stockportfolio.pro
Kyverna Therapeutics, Inc. (KYTX)
Healthcare · Biotechnology · NasdaqGS
Kyverna Therapeutics, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $7.03M | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-28.89M | $-60.37M | $-127.48M | $-161.31M |
| Net margin | -411.3% | — | — | — |
Source: Kyverna Therapeutics, Inc. SEC filings (10-K).
Explore 4 years of Kyverna Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track KYTX in your portfolio →
Kyverna Therapeutics, Inc. financial history by metric
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Kyverna Therapeutics, Inc. — frequently asked questions
What is Kyverna Therapeutics, Inc.'s revenue?
Kyverna Therapeutics, Inc. (KYTX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Kyverna Therapeutics, Inc. profitable?
No — KYTX reported a net loss of $-161.31M in fiscal 2025.
What is KYTX's P/E ratio?
Kyverna Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Kyverna Therapeutics, Inc. have?
As of fiscal year 2025, KYTX carried roughly $24.74M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Kyverna Therapeutics, Inc.'s market cap?
Kyverna Therapeutics, Inc. (KYTX) has a market capitalization of about $478.46M, based on the latest data in our nightly-refreshed cache.
When does Kyverna Therapeutics, Inc.'s fiscal year end?
KYTX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Kyverna Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.